US Patent Issued to Roche Diagnostics Operations on July 8 for "Dynamic of sFlt-1 or endoglin/PIGF ratio as an indicator for imminent preeclampsia and/or HELLP syndrome" (Swiss, German Inventors)

ALEXANDRIA, Va., July 9 -- United States Patent no. 12,352,762, issued on July 8, was assigned to Roche Diagnostics Operations Inc. (Indianapolis).

"Dynamic of sFlt-1 or endoglin/PIGF ratio as an indicator for imminent preeclampsia and/or HELLP syndrome" was invented by Barbara Denk (Groebenzell, Germany) and Martin Hund (Horw, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said firs...